Viridian Therapeutics, Inc./DE (VRDN) Operating cash flow 2016–2025
Viridian Therapeutics, Inc./DE (VRDN) annual operating cash flow history from SEC filings — net cash provided by operating activities each fiscal year.
-$276.4MFY2025 · since FY2016: -$14.8M → -$276.4M
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | -$276.4M | -19.0% |
| FY2024 | -$232.3M | -26.1% |
| FY2023 | -$184.2M | -96.3% |
| FY2022 | -$93.8M | -71.9% |
| FY2021 | -$54.6M | -83.3% |
| FY2020 | -$29.8M | +17.4% |
| FY2019 | -$36.1M | -34.3% |
| FY2018 | -$26.8M | +4.7% |
| FY2017 | -$28.2M | -90.9% |
| FY2016 | -$14.8M | — |
Source: SEC XBRL filings · For reference only · Not investment advice
More VRDN financial trends
VRDN RevenueVRDN Net incomeVRDN Net marginVRDN Gross profitVRDN Gross marginVRDN Operating incomeVRDN Operating marginVRDN Free cash flowVRDN Capital expendituresVRDN Return on equityVRDN Stock buybacksVRDN Dividends paidVRDN Total assetsVRDN Total liabilitiesVRDN Shareholders’ equityVRDN overview →